TENX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tenax Therapeutics Inc (TENX) is not a strong buy at the moment for a beginner investor with a long-term horizon. While there are potential positive catalysts such as the upcoming Phase 3 readout and bullish analyst ratings, the stock presents high risk due to its speculative nature, lack of revenue, and negative financial performance. The technical indicators and options data do not suggest a strong entry point currently.
The MACD histogram is negative (-0.158) and contracting, indicating weak momentum. RSI at 45.063 is neutral, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level (14.092) with resistance at 14.835 and support at 13.349. Overall, the technical indicators suggest a neutral to slightly bearish trend.
Upcoming Phase 3 readout for TNX-103 in Q3 2026, which could be a game-changer if successful.
Bullish analyst ratings with high price targets ($27-$
and predictions of significant upside potential.
Appointment of an experienced CFO, which could improve financial management and investor confidence.
The company has no revenue and continues to operate at a loss (-$15.54M in Q4 2025).
High-risk speculative nature tied to the success of a single drug candidate.
Neutral trading sentiment from hedge funds and insiders, with no significant recent activity.
In Q4 2025, Tenax reported no revenue, a net loss of $15.54M (up 147.96% YoY), and EPS of -0.38 (up 123.53% YoY). While the YoY improvement in net income and EPS is notable, the lack of revenue and negative gross margin are concerning for long-term investors.
Analysts are bullish on TENX, with Cantor Fitzgerald, Guggenheim, and LifeSci Capital all issuing buy or outperform ratings. Price targets range from $27 to $35, reflecting optimism about the upcoming Phase 3 readout. However, analysts also highlight the high-risk, high-reward nature of the stock.
